Kinnate Biopharma Inc [KNTE] stock prices are up 4.86% to $2.59 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KNTE shares have gain 3.19% over the last week, with a monthly amount glided 9.28%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, March 2024, Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories. In a post published today on Yahoo Finance, Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
From an analyst’s perspective:
Kinnate Biopharma Inc [NASDAQ: KNTE] stock has seen the most recent analyst activity on November 17, 2022, when Stifel downgraded its rating to a Hold and also revised its price target to $11 from $35. Previously, H.C. Wainwright started tracking the stock with Buy rating on July 28, 2022, and set its price target to $33. On September 27, 2021, Jefferies initiated with a Buy rating and assigned a price target of $46 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $32 on September 23, 2021. William Blair initiated its recommendation with a Outperform. In a note dated December 28, 2020, Wedbush initiated an Outperform rating and provided a target price of $48 on this stock.
The stock price of Kinnate Biopharma Inc [KNTE] has been fluctuating between $1.04 and $7.18 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Kinnate Biopharma Inc [NASDAQ: KNTE] shares were valued at $2.59 at the most recent close of the market. An investor can expect a potential return of 1058.3% based on the average KNTE price forecast.
Analyzing the KNTE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -0.61 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.56 points at the first support level, and at 2.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.63, and for the 2nd resistance point, it is at 2.68.
Kinnate Biopharma Inc [KNTE] reported earnings per share of -$0.65 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.67/share, meaning a difference of $0.02 and a surprise factor of 3.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.68 per share as compared to estimates of -$0.75 per share, a difference of $0.07 representing a surprise of 9.30%.
Ratios To Look Out For
It’s worth pointing out that Kinnate Biopharma Inc [NASDAQ:KNTE]’s Current Ratio is 10.80. In addition, the Quick Ratio stands at 10.80 and the Cash Ratio stands at 3.28.
Transactions by insiders
Recent insider trading involved Tananbaum James B., Director, that happened on May 08 when 1.78 million shares were purchased. 10% Owner, Foresite Capital Management IV completed a deal on May 08 to buy 1.78 million shares. Meanwhile, Director GORDON CARL L bought 0.98 million shares on May 05.
